This page is free to read, and it stops after 5 rows. Those are the 5 most recently posted filings for this company, out of 9. Reading the whole list, and what each filing says: its issues, the agencies contacted and the lobbyists named, is part of the subscription. So is sorting the list by the reported amount. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.
Before 2025, these bars cover only the lobbying relationships that were still active in 2025 or later. Engagements that ended earlier are not included, so those years may be higher than shown.
Reported income
Recent activity
Register facts only. Everything on this page comes from filings made under the Lobbying Disclosure Act of 1995 and kept by the Secretary of the Senate. We read the filings, we link a client to a listed company where a reviewed rule allows it, and we add nothing else. No score, no ranking and no judgement is attached to lobbying on this site. See the methodology and about this site.
| Registrant | Filing | Amount | Posted | Source | Registrant | Amount | Filing | All amounts | Posted | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | 1st Quarter - Report1st Quarter 2025 | $39,000incomeposted Apr 9, 2025 | Apr 9, 2025 | LD-2 at lda.gov | HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | $39,000 | 1st Quarter - Report1st Quarter 2025 | $39,000income | Apr 9, 2025 | LD-2 at lda.gov |
| HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | 4th Quarter - Report4th Quarter 2024 | $39,000incomeposted Jan 10, 2025 | Jan 10, 2025 | LD-2 at lda.gov | HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | $39,000 | 4th Quarter - Report4th Quarter 2024 | $39,000income | Jan 10, 2025 | LD-2 at lda.gov |
| HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | 3rd Quarter - Report3rd Quarter 2024 | $13,000incomeposted Oct 7, 2024 | Oct 7, 2024 | LD-2 at lda.gov | HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | $13,000 | 3rd Quarter - Report3rd Quarter 2024 | $13,000income | Oct 7, 2024 | LD-2 at lda.gov |
| HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | 2nd Quarter - Report2nd Quarter 2024 | $39,000incomeposted Jul 9, 2024 | Jul 9, 2024 | LD-2 at lda.gov | HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | $39,000 | 2nd Quarter - Report2nd Quarter 2024 | $39,000income | Jul 9, 2024 | LD-2 at lda.gov |
| HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | 1st Quarter - Report1st Quarter 2024 | $39,000incomeposted Apr 9, 2024 | Apr 9, 2024 | LD-2 at lda.gov | HALL, RENDER, KILLIAN, HEATH & LYMAN, P.C.for TELIX PHARMACEUTICALS, INC. | $39,000 | 1st Quarter - Report1st Quarter 2024 | $39,000income | Apr 9, 2024 | LD-2 at lda.gov |
The link between the client names above and TLX is a reviewed rule of ours, not something the filing states: an LD-2 names a client and carries no ticker, no CIK and no LEI.